IBCL-675: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM)
Dima El‐Sharkawi(Royal Marsden Hospital), Nirav N. Shah(Medical College of Wisconsin), Pam McKay(Beatson West of Scotland Cancer Centre), David Lewis(Derriford Hospital), Graham P. Collins(Churchill Hospital), Scott F. Huntington(Yale University), Sarah G. Injac(Baylor College of Medicine), Astrid E. Pulles(University Hospital Heidelberg), Zulfa Omer(University of Cincinnati), Alvaro J. Alencar(University of Miami), Kim Linton(The Christie NHS Foundation Trust), Mary Gleeson(Sarah Cannon Research Institute), Talha Munir(Leeds Teaching Hospitals NHS Trust)
Cited by 1
Related Papers
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213
Pathophysiology of hemophilic arthropathy and potential targets for therapy
|Pharmacological Research|2016|143